CLE PRESENTATION
Induced Infringement & Skinny Labelling
Hikma v Amarin
Register by March 10
Cost to Attend:
$20.00 per person (Student – In person)
$55.00 per person (In person)
Virtual attendance is available for CIPLA members with DUES PAID. To register for virtual attendance, please email Gabrielle.Gelozin@troutman.com to register for virtual attendance.
Please RSVP using the links above no later than March 10, 2026. When registering, please indicate your dinner selection and the name of the attendee.
On March 12, CIPLA is pleased to host a CLE panel discussion on the Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma, Inc. (No. 24-889), a case involving contentious issues surrounding induced patent infringement liability in the context of skinny labels. One hour of self reporting CLE credits are available.
Our panelists are experts in this area and have authored or co-authored amicus briefs in this case. CIPLA is excited and honored to welcome the following guests as our panelists.
Panelists
William Jay
Goodwin Procter
Mr. Jay is a partner in Goodwin’s Appellate and Supreme Court Litigation practice. Mr. Jay recently authored an Amicus Brief for The Association for Accessible Medicines in support of Petitioners in the Hikma case. Mr. Jay has filed more than 400 briefs in federal and state appeals courts and argued in 12 federal circuits and is a prominent advocate at the Federal Circuit, where he has argued 38 times, filed more than 120 briefs in patent appeals, and been recognized as “Appellate Litigator of the Year” by both Managing IP and LMG Life Sciences. Mr. Jay has particular experience in appellate cases involving intellectual property (including patent, licensing, copyright, and trademark law), financial services, administrative law (with a particular focus on pharmaceutical regulation).
Dr. Aaron Kesselheim, MD, JD, MPH
Harvard Medical School
Dr. Kesselheim is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Dr. Kesselheim recently co-authored an Amicus Brief for 76 scholars of Law, Business, Economics, and Medicine in support of Petitioners in the Hikma case. He created and leads the Program On Regulation, Therapeutics, And Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country.
Janet Linn
Tater, Krinsky, Drogin
Ms. Linn is an intellectual property litigator with extensive experience in pharmaceutical (Hatch-Waxman) patent litigation, and has acted as trial counsel in patent, trade secret and antitrust actions involving pharmaceuticals with annual billion dollar sales. Ms. Linn is currently the Vice Chair of the Food, Drug and Cosmetic Section of the New York State Bar Association.